[1] |
CHEN Chenxin, ZHANG Pengpeng, LIU Yongmei, YE Xiaofei, HE Jia.
Combination of zero-inflated model and Dirichlet process in detection of adverse reaction signals during post-marketing surveillance
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 651-654.
|
[2] |
TIAN Chunhua, WU Guizhi.
Implementation of periodic benefit risk evaluation reports in China
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1382-1384.
|
[3] |
LIU Caiping, CHAO Bao, FENG Yuanzhou, SUN Lan, LUO Yuan, YANG Jingfeng, DONG Wu, WANG Yongan, LI Yueting, ZHAO Baoquan.
Establishment of transgenic zebrafish model regulated by nr1h4 and related studies
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 873-880.
|
[4] |
ZHANG Qiang, DU Pengcheng, MAN Chunrui, SUN Qian.
Network pharmacology of protection against angina pectoris by Ginkgo Biloba
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(2): 158-163.
|
[5] |
YANG Xiaolu, CAO Shan, XIONG Bo, QIN Zhen, XIA Yun, QU Hong.
One case of serious liver injury induced by Xiaojin tablets
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(2): 213-216.
|
[6] |
SUN Qian, CHEN Hong, GUO Xinxin, LIU Shengwei, LIAO Yuan, JIA Lingling.
Network Pharmacology of Luteolin Protecting against Cerebral Ischemia
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(8): 760-762.
|
[7] |
TIAN Chunhua, LIU Wei, LIU Cuili, HOU Yongfang, WANG Dan.
Progress in Implementation of ICH M1 in Post-marketing Monitoring of Drugs in China
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(8): 763-765.
|
[8] |
YANG Yue.
Implementation of Pharmacovigilance System in Drug Administration Law and Application of ICH E2 Guideline
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(2): 65-71.
|
[9] |
LIU Lei, ZHANG Qiongling, WANG Jiyong, DING Shilan, YOU Yun, XIAO Suping.
Bioassay on Aquatic Extract of Processed Radix Aconiti Carmichaeli
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(2): 75-80.
|
[10] |
HOU Yong-fang, DONG Duo, XIONG Wei-yi, LI Lan, LIU Hong-liang, LIU Rui, WAN Bang-xi.
Developement of ICSR E2B Guideline
[J]. Chinese Journal of Pharmacovigilance, 2018, 15(3): 144-146.
|
[11] |
PENG Li-li,SHEN Lu,DONG Duo,LIU Wei,ZHANG Hua,GUO Xue,LI Xing-ling,CHENG Gang.
QPPV and Its Implication for China's Adverse Drug Reaction Monitoring Work
[J]. Chinese Journal of Pharmacovigilance, 2015, 12(2): 89-91.
|
[12] |
ZHANG Xue-mei, GUO Jia-dong, FENG Bian-ling, YANG Shi-min.
Investigation on Work State of Adverse Drug Reaction Reporting in Some West Provinces
[J]. Chinese Journal of Pharmacovigilance, 2015, 12(12): 740-743.
|
[13] |
ZHANG Gui-ju, CHU Xiao-yi, TIAN Yue-jie, HUANG Lin, LI Yu-ji.
Implication of EU Pharmacovigilance System to China
[J]. Chinese Journal of Pharmacovigilance, 2015, 12(10): 593-596.
|
[14] |
YUAN Xing-dong GAO Jing ZHOU Juan ZHONG Chang-ming REN Jing-tian.
The Status and Prospective of PSUR in China
[J]. Chinese Journal of Pharmacovigilance, 2014, 11(6): 333-335.
|
[15] |
LUAN Yong-fu, SUN Rong.
Determination of Six Kinds of Aconitum Alkaloids in Aconitum Carmichaeli and Its Samples by HPLC
[J]. Chinese Journal of Pharmacovigilance, 2014, 11(5): 271-274.
|